ESMO

ESMO I-O: Roche silences Tecentriq doubters with latest lung cancer analysis
ESMO I-O: Roche silences Tecentriq doubters with latest lung cancer analysis
Fierce Pharma
ESMO
Roche
Tecentriq
non-small cell lung cancer
Flag link:
Here's Why Seattle Genetics Climbed 17.6% in September
Here's Why Seattle Genetics Climbed 17.6% in September
Motley Fool
Seattle Genetics
ESMO
clinical trials
tucatinib
colorectal cancer
enfortumab vedotin
urothelial cancer
Flag link:
3 Drug Stocks Poised for Gains After Cancer Conference
3 Drug Stocks Poised for Gains After Cancer Conference
Investopedia
ESMO
cancer
Amgen
Incyte
Bristol-Myers Squibb
Flag link:
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
Xconomy
ESMO
PARP inhibitors
prostate cancer
KRAS
Seattle Genetics
AstraZeneca
Merck
GSK
Amgen
breast cancer
Roche
Pfizer
Flag link:
Seattle Genetics makes case it can be more than Adcetris
Seattle Genetics makes case it can be more than Adcetris
Biopharma Dive
Seattle Genetics
Adcetris
clinical trials
ESMO
enfortumab vedotin
Astellas
tucatinib
Flag link:
ESMO: Agios celebrates milestone win for ivosidenib in tough-to-treat bile duct cancer
ESMO: Agios celebrates milestone win for ivosidenib in tough-to-treat bile duct cancer
Fierce Pharma
Agios
bile duct cancer
Tibsovo
ESMO
Flag link:
ESMO: Merck, Eisai detail Keytruda-Lenvima combo results after triple endometrial cancer OK
ESMO: Merck, Eisai detail Keytruda-Lenvima combo results after triple endometrial cancer OK
Fierce Pharma
Merck
Eisai
Keytruda
Lenvima
endometrial cancer
ESMO
Flag link:
ESMO: AstraZeneca eyes payer boost with Tagrisso's latest survival win
ESMO: AstraZeneca eyes payer boost with Tagrisso's latest survival win
Fierce Pharma
AstraZeneca
Tagrisso
EGFR lung cancer
ESMO
Flag link:
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use
Yahoo/Reuters
GSK
AstraZeneca
ESMO
ovarianc cancer
PARP inhibitors
Lynparza
Zejula
Flag link:
ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win
ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win
Fierce Pharma
Roche
Avastin
ovarian cancer
AstraZeneca
Merck
Lynparza
ESMO
Flag link:
Colon cancer proves tougher target for Amgen's KRAS drug
Colon cancer proves tougher target for Amgen's KRAS drug
Biopharma Dive
Amgen
colon cancer
ESMO
KRAS
Flag link:
ESMO: Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers
ESMO: Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers
Fierce Biotech
Seattle Genetics
Astellas
enfortumab vedotin
bladder cancer
ESMO
urothelial cancer
Flag link:
Updated Erleada Data Shows Reduced Risk of Death in Prostate Cancer Patients
Updated Erleada Data Shows Reduced Risk of Death in Prostate Cancer Patients
BioSpace
Erleada
Janssen
JNJ
ESMO
prostate cancer
Flag link:
Shiny, new and expensive: ESMO studies find new cancer drugs carry higher prices, add little benefit
Shiny, new and expensive: ESMO studies find new cancer drugs carry higher prices, add little benefit
Fierce Pharma
cancer
ESMO
drug pricing
oncology
Flag link:
Samsung Bioepis announces phase 3 results of SB8, Bevacizumab biosimilar candidate, at ESMO 2019 Congress
Samsung Bioepis announces phase 3 results of SB8, Bevacizumab biosimilar candidate, at ESMO 2019 Congress
Pharmaceutical Business Review
ESMO
Samsung Bioepis
clinical trials
SB8
biosimilars
bevacizumab
non-small cell lung cancer
Flag link:
GSK and AstraZeneca's PARP Inhibitors Will Flex Their Muscles at ESMO
GSK and AstraZeneca's PARP Inhibitors Will Flex Their Muscles at ESMO
BioSpace
GSK
AstraZeneca
PARP inhibitors
ESMO
Lynparza
Zejula
Flag link:
Esmo 2019 preview – immunotherapies grab the rest of the late-breaker focus
Esmo 2019 preview – immunotherapies grab the rest of the late-breaker focus
EP Vantage
ESMO
Keytruda
Tecentriq
Merck
Roche
Flag link:
ESMO 2019 preview – PARPs on parade
ESMO 2019 preview – PARPs on parade
EP Vantage
ESMO
PARP inhibitors
Lynparza
AstraZeneca
ovarian cancer
GSK
Zejula
Flag link:
ESMO18: Novartis PI3K combo therapy boosts survival in subset of breast cancer patients
ESMO18: Novartis PI3K combo therapy boosts survival in subset of breast cancer patients
Fierce Biotech
Europe
Novartis
ESMO
AstraZeneca
breast cancer
BYL719
Flag link:
#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage
#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage
Endpoints
ESMO
Eli Lilly
Pfizer
Novartis
abemaciclib
breast cancer
Flag link:

Pages